Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

Stock Information for Profire Energy Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Profire Energy Inc.

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
ALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term Stockholders
UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.